Just Biotherapeutics and Teva enter an agreement for the design and development of a high productivity (HP) biomanufacturing process
Seattle, USA, 28 June 2019:
Just Biotherapeutics, Inc. ("Just.Bio"), an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics, announced today that they have entered into an agreement with Teva for the design and development of a high productivity (HP) biomanufacturing process.
For further information, click here to read Just.Bio's full press release.
